We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Astria Therapeutics Inc | NASDAQ:ATXS | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.44 | -4.33% | 9.73 | 7.00 | 15.45 | 10.27 | 9.4501 | 10.15 | 443,655 | 05:00:06 |
Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that it will present final STAR-0215 Phase 1a healthy subject data at the upcoming American Academy of Allergy, Asthma, & Immunology (AAAAI) Annual Meeting in Washington, D.C. on February 23, 2024 at 3:15pm EST.
Dr. William Lumry, M.D., Clinical Professor of Internal Medicine at the University of Texas Health Science Center at Dallas, will present a poster titled, “Updated Results from a Phase 1a Trial of STAR-0215 for Hereditary Angioedema” at 3:15pm EST in the Convention Center, Level 2, Hall D, poster number 032.
About Astria Therapeutics:
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema. Our second program, STAR-0310, is a monoclonal antibody OX40 antagonist in preclinical development for the treatment of atopic dermatitis. Learn more about our company on our website, www.astriatx.com, or follow us on X and Instagram @AstriaTx and on Facebook and LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240220427055/en/
Astria:
Investor Relations and Media: Elizabeth Higgins investors@astriatx.com
1 Year Astria Therapeutics Chart |
1 Month Astria Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions